A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

This study is comparing three treatment approaches for women with a rare gynecological cancer called recurrent clear cell carcinoma (found in the ovaries, uterus, cervix, vagina, or vulva). The three arms are: an immunotherapy drug alone (dostarlimab), immunotherapy plus bevacizumab (a drug that cuts off blood supply to tumors), or standard chemotherapy. Clear cell carcinoma often doesn't respond well to regular chemo, making new approaches important. **You may be eligible if...** - You are a woman aged 18 or older - You have a confirmed diagnosis of recurrent clear cell carcinoma of the ovary, endometrium, cervix, vagina, or vulva - Your cancer progressed within 12 months of completing platinum-based chemotherapy - You have had 1 to 5 prior treatment regimens - You are otherwise healthy enough to participate (ECOG performance status 0 or 1) **You may NOT be eligible if...** - You have had 6 or more prior chemotherapy regimens - You have previously received immunotherapy drugs (anti-PD-1/PD-L1) - You have uncontrolled high blood pressure or active bleeding problems - You have active, uncontrolled brain metastases Talk to your doctor to see if this trial is right for you.